A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether it is better to start an anti-HIV regimen containing a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a PI in combination with an NNRTI. This study will also examine which treatment regimen is best as a first treatment for HIV infection.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Abacavir; Didanosine; Efavirenz; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Stavudine

Criteria

Inclusion Criteria:

• HIV infected

• Agree to practice abstinence or to use barrier methods of birth control during the study

• Are at least 13 years old or have signed informed consent from legal guardian for patients between the ages of 13 and 18

Exclusion Criteria:

• Have ever taken any anti-HIV drugs

• Are unable to complete the study for any reason

• Pregnancy

• Breastfeeding

• Any condition that, in the investigator's opinion, may interfere with the study